We already know that K has been beyond successful on nearly every outcome: p21 increased presence, tumor arrest and reduction, safety established above the bottom of anticipated high efficacy range, no DLTs going into the 7th cohort, lots of subjects receiving multiple cycle of the drug for which there must be a perceived benefit for the previous cycle.
Sorry, but K is already a success and will clearly be effective in combination therapies. But, of course, CTIX is the reverse exception to increased value as a trial progresses and as new trials are added, some of which have majority funding arranged by the host institution.
News 
Market Data 
Discover 
